Saito Y, Kobayashi Y. Contemporary coronary drug-eluting and coated stents: an updated mini-review (2023). Cardiovasc Interv Ther. 2024;39:15–7.

Article  PubMed  Google Scholar 

Ozaki Y, Tobe A, Onuma Y, Kobayashi Y, Amano T, Muramatsu T, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024. Cardiovasc Interv Ther. 2024;39:335–75.

Article  PubMed  PubMed Central  Google Scholar 

Matsuhiro Y, Egami Y, Okamoto N, Kusuda M, Sakio T, Nohara H, et al. Early vascular healing of ultra-thin strut polymer-free sirolimus-eluting stents in acute coronary syndrome: USUI-ACS study. Cardiovasc Interv Ther. 2023;38:55–63.

Article  CAS  PubMed  Google Scholar 

Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2023;38:166–76.

Article  PubMed  PubMed Central  Google Scholar 

Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (London, England). 2008;371:899–907.

Article  CAS  PubMed  Google Scholar 

Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122:2301–12.

Article  CAS  PubMed  Google Scholar 

Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–53.

Article  PubMed  Google Scholar 

Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption: five-year follow-up from the ABSORB III trial. Circulation. 2019;140:1895–903.

Article  CAS  PubMed  Google Scholar 

Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940.

Article  PubMed  PubMed Central  Google Scholar 

Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, Buck T, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19:232–9.

PubMed  PubMed Central  Google Scholar 

Jinnouchi H, Torii S, Sakamoto A, Kolodgie FD, Virmani R, Finn AV. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat Rev Cardiol. 2019;16:286–304.

Article  CAS  PubMed  Google Scholar 

Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578–88.

Article  CAS  PubMed  Google Scholar 

Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–15.

Article  CAS  PubMed  Google Scholar 

Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 2017;70:2852–62.

Article  CAS  PubMed  Google Scholar 

Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, et al. 5-Year outcomes after bioresorbable coronary scaffolds implanted with improved technique. J Am Coll Cardiol. 2023;82:183–95.

Article  PubMed  Google Scholar 

Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet (London, England). 2016;387:537–44.

Article  CAS  PubMed  Google Scholar 

Elias J, van Dongen IM, Kraak RP, Tijssen RYG, Claessen B, Tijssen JGP, et al. Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: a weighted meta-analysis of seven randomised controlled trials including 5577 patients. Neth Heart J. 2017;25:429–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, et al. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39:3381–9.

Article  PubMed  Google Scholar 

Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921–31.

Article  PubMed  Google Scholar 

Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12:1747–56.

Article  PubMed  Google Scholar 

Cuculi F, Puricel S, Jamshidi P, Valentin J, Kallinikou Z, Toggweiler S, et al. Optical coherence tomography findings in bioresorbable vascular scaffolds thrombosis. Circ Cardiovasc Interv. 2015;8: e002518.

Article  CAS  PubMed  Google Scholar 

Yamaji K, et al. Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry. J Am Coll Cardiol. 2017;70:2330–44.

Article  CAS  PubMed  Google Scholar 

Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330–42.

Article  CAS  PubMed  Google Scholar 

Tellez A, Afari ME, Buszman PP, Seifert P, Cheng Y, Milewski K, et al. Peri-strut low-intensity areas in optical coherence tomography correlate with peri-strut inflammation and neointimal proliferation: an in-vivo correlation study in the familial hypercholesterolemic coronary swine model of in-stent restenosis. Coron Artery Dis. 2014;25:595–601.

Article  PubMed  Google Scholar 

Sato T, Jose J, El-Mawardy M, Sulimov DS, Tolg R, Richardt G, et al. Relationship between peri-strut low intensity areas and vascular healing response after everolimus-eluting bioresorbable scaffold implantation: an optical coherence tomography study. J Cardiol. 2017;69:606–12.

Article  PubMed  Google Scholar 

Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. J Am Coll Cardiol. 2017;70:60–74.

Article  CAS  PubMed  Google Scholar 

Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391–9.

Article  PubMed  Google Scholar 

Radu MD, Engstrom T. Casting light on coronary evaginations: different mechanisms in different coronary devices? Eur Heart J. 2016;37:2050–4.

Article  PubMed  Google Scholar 

Virmani R, Jinnouchi H, Finn AV. Discontinuity: is it a major cause of scaffold thrombosis? J Am Coll Cardiol. 2017;70:2345–8.

Article  PubMed  Google Scholar 

Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb everolimus-eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B trial (A clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2014;7:1400–11.

Article  PubMed